These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 10597192)

  • 1. Expression of the tumor-rejection antigen SART1 in brain tumors.
    Imaizumi T; Kuramoto T; Matsunaga K; Shichijo S; Yutani S; Shigemori M; Oizumi K; Itoh K
    Int J Cancer; 1999 Dec; 83(6):760-4. PubMed ID: 10597192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of the SART1 tumor-rejection antigen in human osteosarcomas.
    Ishida H; Komiya S; Inoue Y; Yutani S; Inoue A; Itoh K
    Int J Oncol; 2000 Jul; 17(1):29-32. PubMed ID: 10853014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of the SART1 tumor-rejection antigen in hepatocellular carcinomas.
    Yutani S; Shichijo S; Inoue Y; Kawagoe N; Okuda K; Kurohiji T; Tanaka M; Sata M; Itoh K
    Oncol Rep; 2001; 8(2):369-72. PubMed ID: 11182058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of the SART1 tumor rejection antigen in renal cell carcinoma.
    Shintaku I; Kawagoe N; Yutani S; Hoshi S; Orikasa S; Yoshizumi O; Itoh K
    Urol Res; 2000 Jun; 28(3):178-84. PubMed ID: 10929426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokines required for induction of histocompatibility leukocyte antigen-class I-restricted and tumor-specific cytotoxic T lymphocytes by a SART1-derived peptide.
    Matsunaga K; Nakao M; Masuoka K; Inoue Y; Gouhara R; Imaizumi T; Nishizaka S; Itoh K
    Jpn J Cancer Res; 1999 Sep; 90(9):1007-15. PubMed ID: 10551332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of the SART1 tumor-rejection antigens in colorectal cancers.
    Sasatomi T; Yamana H; Shichijo S; Tanaka S; Okamura T; Ogata Y; Itoh K; Shirouzu K
    Dis Colon Rectum; 2000 Dec; 43(12):1754-8. PubMed ID: 11156463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of HLA-A2- and A24-restricted T-cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy.
    Ueda R; Ohkusu-Tsukada K; Fusaki N; Soeda A; Kawase T; Kawakami Y; Toda M
    Int J Cancer; 2010 Feb; 126(4):919-29. PubMed ID: 19728337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of the SART3 tumor-rejection antigen in brain tumors and induction of cytotoxic T lymphocytes by its peptides.
    Murayama K; Kobayashi T; Imaizumi T; Matsunaga K; Kuramoto T; Shigemori M; Shichijo S; Itoh K
    J Immunother; 2000; 23(5):511-8. PubMed ID: 11001544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a human leukocyte antigen-A24-restricted T-cell epitope derived from interleukin-13 receptor alpha2 chain, a glioma-associated antigen.
    Shimato S; Natsume A; Wakabayashi T; Tsujimura K; Nakahara N; Ishii J; Ito M; Akatsuka Y; Kuzushima K; Yoshida J
    J Neurosurg; 2008 Jul; 109(1):117-22. PubMed ID: 18590440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of human leukocyte antigen-A26-restricted and tumor-specific cytotoxic T lymphocytes by a single peptide of the SART1 antigen in patients with cancer with different A26 subtypes.
    Inoue Y; Nakao M; Matsunaga K; Kikuchi M; Gomi S; Toh U; Takamori S; Yamana H; Itoh K
    J Immunother; 2000; 23(3):296-303. PubMed ID: 10838658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinesin superfamily protein-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A24+ glioma patients.
    Harada M; Ishihara Y; Itoh K; Yamanaka R
    Oncol Rep; 2007 Mar; 17(3):629-36. PubMed ID: 17273744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of a human leukocyte antigen-A24-restricted antitumor cell with the use of SART-1 peptide and dendritic cells in patients with malignant brain tumors.
    Yoshida S; Tanaka R
    J Lab Clin Med; 2004 Oct; 144(4):201-7. PubMed ID: 15514588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a SART-1-derived peptide capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes.
    Kikuchi M; Nakao M; Inoue Y; Matsunaga K; Shichijo S; Yamana H; Itoh K
    Int J Cancer; 1999 May; 81(3):459-66. PubMed ID: 10209962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes.
    Yamada A; Kawano K; Koga M; Matsumoto T; Itoh K
    Cancer Res; 2001 Sep; 61(17):6459-66. PubMed ID: 11522641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of tumor-rejection antigens in gynecologic cancers.
    Tanaka S; Tsuda N; Kawano K; Sakamoto M; Nishida T; Hashimoto T; Shichijo S; Kamura T; Itoh K
    Jpn J Cancer Res; 2000 Nov; 91(11):1177-84. PubMed ID: 11092984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of individual specific cytotoxic T lymphocytes for two MAGE-3-derived epitopes presented by HLA-A24.
    Katsura F; Eura M; Chikamatsu K; Oiso M; Yumoto E; Ishikawa T
    Jpn J Clin Oncol; 2000 Mar; 30(3):117-21. PubMed ID: 10798537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
    Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
    Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-cell receptor Vbeta gene usage by T cells reactive with the tumor-rejection antigen SART-1 in oral squamous cell carcinoma.
    Kumamaru W; Nakamura S; Kadena T; Yamada A; Kawamura E; Sasaki M; Ohyama Y; Toyoshima T; Hayashida JN; Itoh K; Shirasuna K
    Int J Cancer; 2004 Feb; 108(5):686-95. PubMed ID: 14696095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of a newly defined tumor-rejection antigen SART3 in musculoskeletal tumors and induction of HLA class I-restricted cytotoxic T lymphocytes by SART3-derived peptides.
    Tsuda N; Murayama K; Ishida H; Matsunaga K; Komiya S; Itoh K; Yamada A
    J Orthop Res; 2001 May; 19(3):346-51. PubMed ID: 11398844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of the SART3 antigens in oral cancers.
    Fukuda K
    Kurume Med J; 2001; 48(1):55-8. PubMed ID: 11402621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.